Emerging Biopharma

Constellation Orion
Biotech

Oryon shines out of stealth with $21M to fight Parkinson's

Oryon Cell Therapies is launching with a $21 million series A round and announcing that physician entrepreneur Ron Cohen, M.D., will be its CEO.
Will Maddox Mar 23, 2026 5:00am
F1 Racetrack

R1 debuts with $77.5M to advance kidney disease treatment

Mar 17, 2026 7:00am
One extinguished candle on dark background

Biotech unit Pfizer Ignite flames out

Mar 12, 2026 3:58pm
Deal

French biotech pens $128M deal for Kezar protein degrader work

Mar 12, 2026 9:00am
phoenix rising from the flames

Atrium arises from Avidity buyout with $270M, preclinical assets

Feb 27, 2026 11:05am
harbor at sunset

Harbour sails with Solstice in $1.1B biobucks deal

Feb 24, 2026 2:38pm
More News

New biotech Slate aims to solve migraine injection equation

Feb 24, 2026 7:30am

Korsana crosses into crowded Alzheimer's field with $175M

Feb 18, 2026 6:00am

Priovant will move brepocitinib to phase 3 after midstage win

Feb 6, 2026 7:00am

Fortitude has faith glue degraders can beat ADC resistance

Jan 26, 2026 10:47am